Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance

Taking stock of the drug industry, from the lab to the medicine chest

September 4, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

novartis STAT+ | Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance The company is the leading producer of radiopharmaceutical or radioligand therapies, an emerging type of cancer treatment. By Allison DeAngelis Moderna reports encouraging results on its mpox vaccine, as outbreaks in Africa spread None of the macaques that were vaccinated with the experimental Moderna vaccine, mRNA-1769, developed "severe" disease. By Helen Branswell STAT+ | Drug aimed at strengthening neurons to treat Alzheimer's fails in trial Fosgonimeton, aimed at protecting neurons, failed to do better than placebo at slowing cognitive decline in patients with mild or moderate Alzheimer's. By Jason Mast Spencer Platt/Getty Images Trying to time your vaccines just right? There are no easy answers, but here are some factors to consider Guidance on timing seasonal shots for maximum protection against influenza, RSV, and Covid. All at once is fine, but delaying some can be advantageous. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser